3-D Matrix Medical Technology’s PuraStat® Hemostatic Gel Featured by Key Opinion Leaders at Digestive Disease Week®

Newton, MA, May 26, 2022 (GLOBE NEWSWIRE) — PuraStat®a hemostatic agent manufactured by 3-D Matrix Medical Technology, a leading global peptide solutions company, was highlighted in several key presentations by key opinion leaders at the recent Digestive Disease Week® (DDW).

On Sunday 22 May, Professor Pradeep Bhandari (Queen Alexandra Hospital, UK) spoke about post-polypectomy bleeding and related his clinical experience with PuraStat in the context of alternative haemostatic techniques. He highlighted the procedural advantages of PuraStat, including its ease of use and speed of application.

He concluded his presentation by saying, “In our hands, we have seen a significant reduction in delayed bleeding rates. We have used it on over 550 patients in the UK with very good results. PuraStat is an effective tool for resolving intra-procedural complications. “

Additionally, on Monday May 23, Professor Allesandro Repici (Humanitas Research Hospital, Italy) performed a live endoscopy session during which he demonstrated the application of PuraStat hemostatic gel in an endoscopic resection procedure of the mucosa (EMR) post-step by step. Professor Repici provided real-time visual evidence of how PuraStat enables precise application for the prevention of post-operative bleeding.

As part of his discussion, he commented, “PuraStat is very easy to deliver. You can see how accurate you can be with a very nice protective layer. Data from a multicenter registry and a randomized trial show that it can significantly reduce delayed bleeding.”

“We are thrilled that Professors Bhandari and Repici are amplifying their clinical belief that PuraStat is a valuable and effective part of their toolkit,” commented Toshi Amanuma, General Manager of 3-D Matrix North America. “As we approach our full commercial launch in the United States next month, we look forward to collaborating with US-based gastrointestinal endoscopists to help control delayed bleeding, make endoscopic procedures safer, and improve patient care.”

The management of intra-procedural bleeding in the gastrointestinal tract is crucial to improve the practice of general gastrointestinal procedures as well as endoscopic resection procedures such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) and endoscopic retrograde cholangiopancreatography (ERCP). Both active and non-bleeding bleeding vessels are traditionally electrically cauterized by endo-knives or hemostatic forceps during resection, but may increase the incidence of delayed complications such as bleeding or perforation related to thermal tissue damage.

PuraStat’s Hemostatic Gel comprises a unique self-assembling synthetic peptide designed to reduce delayed bleeding and achieve hemostasis during endoscopic procedures in the gastrointestinal tract. Its transparent construction allows for visual confirmation of bleeding status and is easily applied with ready-to-use pre-filled syringes. PuraStat has been cleared by the U.S. FDA for hemostasis of mild to moderate post-ESD or EMR bleeding, as adjunctive, bridging, prophylactic, or rescue therapy for intraprocedural venous bleeding, or as prophylactic therapy for prevent postoperative bleeding, as well as for the management symptoms of rectal mucositis, such as radiation proctitis which can be caused by chemotherapy or radiotherapy. PuraStat will be commercially available in the United States in June 2022.

About 3-D Matrix Medical Technologies

Founded in 2004 as a spin-off from MIT, 3-D Matrix has grown to become one of the world’s leading peptide solutions companies headquartered in Tokyo, Japan. With offices serving the Americas, Europe and Asia, our employees as well as our partners and distributors serve researchers, healthcare providers and patients around the world. www.3dmatrix.com/us/

About Digestive Diseases Week®

Digestive Diseases Week® (DDW) is the largest international gathering of physicians, researchers and scholars in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting May 21-24, 2022. The meeting features over 3,100 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.


Kotaro Watanabe
3-D Matrix Medical Technology
[email protected]

About Florence L. Silvia

Check Also

Health Care Payment Integrity Report

Codoxo named powerful player “Collaborating with our customers and applying our innovative AI to their …